Abstract

Formulation, Physical Stability, and the Clinical Effectiveness of Extemporaneous Ivermectin Oral Solution

Author(s): Zaid Abdel-Naser, Zaaror Yara Abu, Qaddumi Aiman, Ratrout Ala, Ahmad Ayda, Hamad Emad, Kittana Naim

Issue: Nov/Dec 2021 - Volume 25, Number 6

Page(s): 523-527

Download in electronic PDF format for $75
  • Formulation, Physical Stability, and the Clinical Effectiveness of Extemporaneous Ivermectin Oral Solution Page 1
  • Formulation, Physical Stability, and the Clinical Effectiveness of Extemporaneous Ivermectin Oral Solution Page 2
  • Formulation, Physical Stability, and the Clinical Effectiveness of Extemporaneous Ivermectin Oral Solution Page 3
  • Formulation, Physical Stability, and the Clinical Effectiveness of Extemporaneous Ivermectin Oral Solution Page 4
  • Formulation, Physical Stability, and the Clinical Effectiveness of Extemporaneous Ivermectin Oral Solution Page 5

Abstract

Ivermectin is a gamma amino butyric acid (GABA)-gated-Cl-channels modulator, which has been used orally in the treatment of numerous parasitic infections. The study target was to set up a stable, efficient 0.2% w/v ivermectin solution, which would be achieved from pure ivermectin powder as a source of the active pharmaceutical ingredient. Several trial solutions were prepared. The most fitting solution, with respect to its organoleptic properties, was chosen for additional investigation, including the solution’s physical stability. Two storage conditions, room temperature (25°C, 60% relative humidity) and accelerated stability chambers (40°C, 75% relative humidity) were subjected to guarantee the physical stability of the solution through the 3-month study period. Furthermore, other quality tests were assessed, (e.g., pH, assay, organoleptic properties, microbial contamination) for the same latter period. Quantification of ivermectin was validated utilizing a high-performance liquid chromatography analytical method. The adopted solution showed accepted organoleptic properties. The pH of the solutions was approximately 5 and remained unchanged during the stability study. The mean percent of remained ivermectin solution was close to 97% ± 0.2 at room temperature. Ivermectin solution was additionally tested for microbial contamination, and it was free from any microbial contamination (E. coli bacteria: Negative/mL, yeast and molds count: <10 cfu/mL and aerobic microbial count results in <10 cfu/mL). The adopted formula showed the best physical stability within at least the three months of storage at both room and accelerated conditions. Ivermectin solution was successfully prepared from its pure powder. This formula provides a stable, efficient oral solution for those who suffer from swallowing difficulties or patients in the intensive care unit who cannot receive the medication in a solid dosage form. Using the suggested formula, community and hospital pharmacists could prepare an effective, high quality ivermectin oral solution using pure ivermectin powder. 

Related Keywords

Related Categories

Printer-Friendly Version

Related Articles from IJPC

Issue/Page
View/Buy
Title/Author
(Click for Abstract / Details / Purchase)
Nov/Dec 2021
Pg. 523-527
May/Jun 2018
Pg. 240-246
Jan/Feb 2016
Pg. 41-45
Author(s): Akers Michael J
Jul/Aug 2017
Pg. 322-329
Mar/Apr 2004
Pg. 147-152
Jan/Feb 2004
Pg. 46-48
Author(s): Allen Loyd V Jr
Sep/Oct 2003
Pg. 389-393
Jan/Feb 2001
Pg. 9-12
Author(s): Schotik Debora
Mar/Apr 2016
Pg. 137-141
Author(s): Akers Michael J
Jul/Aug 2020
Pg. 327-336
May/Jun 2023
Pg. 250-255
Sep/Oct 2025
Pg. 387-404
Mar/Apr 2014
Pg. 152-158
Sep/Oct 2016
Pg. 438-439
Jan/Feb 2002
Pg. 66-69
Jan/Feb 2002
Pg. 70-73
May/Jun 2003
Pg. 233-239
Jan/Feb 2023
Pg. 72-77
Sep/Oct 2010
Pg. 430-435
Nov/Dec 2018
Pg. 504-511